Pharmacotherapies Flashcards
bisphosphonates common drugs
risedronate & alendronate
bisphosphonates MOA
inhibits farnesyl pyrophosphate synthesis and suppress osteoclast activity
bisphosphonates indication
first line therapy for osteoporosis and treatment of hypercalcemia
bisphosphonates adverse effects
gastric and esophageal irritation, adynamic bone, possible renal failure, rare osteonecrosis of jaw, rare femoral fractures
RANKL inhibitors common drugs
denosumab
RANKL inhibitors MOA
Mab binds to RANKL and prevents it from stimulating osteoclast differentiation and function decreasing bone resorption
RANKL inhibitors indication
osteoporosis with high risk fractures
RANKL inhibitors adverse effects
increased risk of infection, hypocalcemia
SERMs common drugs
raloxifene
SERMs MOA
interacts with estrogen receptor inhibits bone resorption and increase BMD
SERMs indication
osteoporosis in women aged <60,
SERMs adverse effects
increased risk of thromboembolism
calcitonin MOA
binds GPCRs to suppress osteoclastic bone resorption
calcitonin indications
first line for Paget’s disease
calcitonin adverse effects
gastric erosions/bleeding
PTH/PTH analog common drugs
teriparatide
PTH MOA
similar to PTH
PTH indication
osteoporosis in men and women with severe osteoporosis
PTH adverse effects
hypercalcemia, hypercalciuria,
monoclonal anti-sclerostin common drugs
romosuzumab
monoclonal anti-sclerostin MOA
stimulates bone turnover by inhibiting sclerostin by enhancing osteoblast and decrease osteoclast
monoclonal anti-sclerostin indications
osteoporosis in postmenopausal women at high risk for fracture
NSAIDs common drugs
ibuprofen
NSAIDs MOA
inhibit prostaglandin synthesis & inhibit urate crystal formation